In the first half of the year, imports of medical devices showed negative growth.

Pharmaceutical Network September 29th, 2020, affected by the special period, the development potential of the domestic medical device industry has been highlighted, the pace of import substitution accelerated.
first half of 2020, China's medical device import and export trade amounted to US$26.641 billion, up 2.98 percent year-on-year, according to the First Half of 2020 Review of Medical Device Trade.
exports were US$16,313 million, up 22.46 per cent year-on-year, while imports were US$10,328 million, down 20.79 per cent year-on-year.
the first half of China's medical device imports showed negative growth, which also means that domestic medical equipment or ushered in the "bend over-car" opportunities, import replacement space is huge.
Previously, there has been an analysis of the second half of the domestic medical device market, think that the second half of the foreign market demand for medical devices is still huge, and most of the domestic medical device listed companies in the Ministry of Commerce list, which will bring opportunities for the domestic medical device industry.
from the performance of domestic medical devices in the first half of this year, leading enterprises For the first time, Meirui Medical surpassed the leading enterprises in chemical pharmaceuticals and Chinese medicine, with net profit increasing by 45.78 percent year-on-year and brand influence continuing to increase.
In addition, up to now, A-share has 346 listed pharmaceutical and biological enterprises issued the first half of 2020 annual report, in addition to Meirui Medical, there are five medical device companies home net profit growth rate of more than 1000%, including Sanxiang Bio, Anglo Medical, Kantai Medical, Zhende Medical, Oriental Biology.
, although the country also has in the medical device industry to promote the collection, but mainly for high-value consumables, the industry is expected to have a greater impact on multinational enterprises.
In the recent medical high-value consumables belt procurement of the winning list, domestic equipment occupies the majority, many hospitals in the tender announcement explicitly do not accept tenders for imported products, or that non-specifically specified product categories do not accept imported products.
china has been carrying out medical high-value consumables belt procurement in various places, aimed at reducing the burden of patient costs.
, orthopaedic supplies have been issued and executed in 14 provinces, ophthalmology supplies in 8 provinces but not implemented, interventional coronary stent is the first batch of centralized procurement varieties nationwide.
public data show that China's high-value medical supplies market size of 104.6 billion yuan, of which vascular intervention, orthopaedic implants are 38.9 billion yuan and 26.2 billion yuan, respectively.
Industry pointed out that, in fact, the crown stent itself domestic and import price gap has been very large, domestic stent its factory price and the price of access to the hospital difference of 9 times, and import bracket factory price to enter the domestic hospital difference of 6.5 times.
the current crown brace field of domestic and imported products of the technical differences are large, it is expected that with the high-value medical supplies collection and mining, domestic crown support can achieve import substitution.
Overall, China's low- and medium-end medical device products have long been recognized by the international market, in the high-end field has also achieved no small breakthrough, such as most orthopaedic field of medical devices and consumables in terms of quality and performance has been in line with high-end imported products.
In the long run, under the influence of factors such as escalating medical consumption, gradually relaxing registration conditions, accelerating approval procedures, increasingly reasonable prices, expanding the scope of medical insurance reimbursement and increasing opportunities for product hospitalization, the medical device industry will be forced to transition from imitation to innovation, domestic high-end medical device imports to replace or accelerate, for medical device technology research and development, iterative upgrading and so on will put forward higher requirements.
.